Dual Trigger

PreclinicalSmall molecule

WWeill Medical College of Cornell University

Dual Trigger is one of 8 small molecule programs targeting Infertility (IVF Patients). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Infertility (IVF Patients)Enrolling by invitation

OocyteUnknown status

Infertility (IVF Patients)Preclinical

Enrolling by invitation

OocytePreclinical

Unknown status

Competition

Competitive Landscape

6 competitors in Oocyte

#DrugCompanyPhaseTrials

Decapeptyl

SSheba Medical Center

Preclinical

1 2

Ovitrelle

Merck & Co.

Preclinical

1 3

Dual Trigger

WWeill Medical College of Cornell University

Preclinical

1 4

In Vitro Maturation

NNorthwell Health

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oocyte1 trial

The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger

Unknown status·EEmbryolab Fertility Clinic·N/A·NCT06142708·80 enrolled

Oocyte Maturation1 trial

Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders

Completed·—·Phase 3·NCT04224818·140 enrolled

Ovulation1 trial

Study of Dual Trigger Ovulation in Oocyte Donors

Terminated·WWeill Medical College of Cornell University·Phase 4·NCT01443546·26 enrolled

Infertility (IVF Patients)1 trial

Prospective Randomized Single-Blind Study of the Effectiveness of the Superovulation Stimulation Protocol Using hCG Compared to Standard Protocols With Different Gonadotropin Doses in In Vitro Fertilization Programs

Enrolling by invitation·LLTD "EKODNIPRO", Medical centre Medical Plaza Dnipro·Preclinical·NCT07771283·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Dual Trigger. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dual Trigger compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dual Trigger. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Weill Medical College of Cornell University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWeill Medical College of Cornell University

Dual Trigger

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oocyte1 trial

Oocyte Maturation1 trial

Ovulation1 trial

Infertility (IVF Patients)1 trial

References

Drug Info

Quick Facts

Related News